What is Zacks Research’s Estimate for VRTX Q1 Earnings?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Investment analysts at Zacks Research boosted their Q1 2026 earnings estimates for shares of Vertex Pharmaceuticals in a report released on Friday, September 19th. Zacks Research analyst Team now expects that the pharmaceutical company will post earnings of $3.96 per share for the quarter, up from their previous forecast of $3.94. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $15.63 per share. Zacks Research also issued estimates for Vertex Pharmaceuticals’ Q2 2027 earnings at $4.60 EPS and FY2027 earnings at $18.64 EPS.

Several other research firms have also commented on VRTX. Guggenheim decreased their target price on shares of Vertex Pharmaceuticals from $558.00 to $546.00 and set a “buy” rating on the stock in a report on Wednesday, August 6th. Raymond James Financial assumed coverage on shares of Vertex Pharmaceuticals in a report on Tuesday, September 2nd. They issued a “market perform” rating on the stock. UBS Group set a $553.00 target price on shares of Vertex Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, August 5th. HC Wainwright decreased their target price on shares of Vertex Pharmaceuticals from $550.00 to $478.00 and set a “buy” rating on the stock in a report on Tuesday, August 5th. Finally, Morgan Stanley set a $439.00 target price on shares of Vertex Pharmaceuticals and gave the company an “equal weight” rating in a report on Tuesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and thirteen have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $496.05.

Vertex Pharmaceuticals Stock Down 1.0%

VRTX stock opened at $383.12 on Monday. Vertex Pharmaceuticals has a 12 month low of $362.50 and a 12 month high of $519.88. The firm has a market cap of $98.23 billion, a P/E ratio of 27.39 and a beta of 0.44. The company’s 50-day moving average price is $414.44 and its two-hundred day moving average price is $449.84.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share for the quarter, topping the consensus estimate of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The business had revenue of $2.94 billion during the quarter, compared to analysts’ expectations of $2.90 billion. During the same quarter in the previous year, the company earned ($12.83) EPS. The business’s revenue was up 11.3% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS.

Insider Activity

In other news, Director Bruce I. Sachs purchased 5,000 shares of the company’s stock in a transaction dated Wednesday, August 6th. The shares were purchased at an average price of $389.68 per share, for a total transaction of $1,948,400.00. Following the transaction, the director owned 45,000 shares of the company’s stock, valued at approximately $17,535,600. This trade represents a 12.50% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 0.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. United Services Automobile Association acquired a new position in shares of Vertex Pharmaceuticals in the 1st quarter worth approximately $2,933,000. Aries Wealth Management acquired a new position in shares of Vertex Pharmaceuticals in the 1st quarter worth approximately $293,000. New England Research & Management Inc. acquired a new position in shares of Vertex Pharmaceuticals in the 2nd quarter worth approximately $472,000. Paladin Wealth LLC acquired a new position in shares of Vertex Pharmaceuticals in the 2nd quarter worth approximately $552,000. Finally, Andrew Hill Investment Advisors Inc. lifted its position in shares of Vertex Pharmaceuticals by 21.8% in the 2nd quarter. Andrew Hill Investment Advisors Inc. now owns 8,003 shares of the pharmaceutical company’s stock worth $3,563,000 after purchasing an additional 1,430 shares during the period. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.